Abfero Pharmaceuticals Overview
- Year Founded
-
2016
- Status
-
Acquired/Merged
- Employees
-
2
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$225M
Abfero Pharmaceuticals General Information
Description
Developer of iron chelation therapies designed for the treatment of iron overload diseases. The company offers iron-binding molecules, iron overload therapies, neurodegenerative disease treatments, hematological disease treatments, and clinical-stage pharmaceuticals, thereby enabling patients to manage transfusional iron overload through a highly tolerable oral chelating agent.
Contact Information
Website
www.abferopharmaceuticals.com(Operating Subsidiary)
Corporate Office
- Boston, MA 02116-2774
- United States
Corporate Office
- Boston, MA 02116-2774
- United States
Abfero Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 11-Nov-2021 | $225M | Completed | Generating Revenue | ||
| 5. Later Stage VC | 22-Mar-2021 | Completed | Generating Revenue | |||
| 4. Grant | 01-Nov-2020 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 23-Jun-2020 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 11-Apr-2019 | $2.13M | $3.89M | Completed | Generating Revenue | |
| 1. Early Stage VC | 02-May-2018 | $1.75M | $1.75M | Completed | Generating Revenue |
Abfero Pharmaceuticals Comparisons
Industry
Financing
Details
Abfero Pharmaceuticals Competitors (2)
One of Abfero Pharmaceuticals’s 2 competitors is Protagonist Therapeutics, a Formerly VC-backed company based in Newark, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Protagonist Therapeutics | Formerly VC-backed | Newark, CA | ||||
| Bond Biosciences | Venture Capital-Backed | Parkville, MO |
Abfero Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Abfero Pharmaceuticals Patents
Abfero Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3493801-B1 | Dosage regimens with (s)-4,5-dihydro-2-[2-hydroxy-4-(3,6-dioxaheptyloxy)phenyl]-4-methyl-4-thiazolecarboxylic acid for use in treating iron overload | Active | 05-Aug-2016 | ||
| EP-3493801-C0 | Dosage regimens with (s)-4,5-dihydro-2-[2-hydroxy-4-(3,6-dioxaheptyloxy)phenyl]-4-methyl-4-thiazolecarboxylic acid for use in treating iron overload | Active | 05-Aug-2016 | ||
| ES-3063079-T3 | Dosage regimens with (s)-4,5-dihydro-2-[2-hydroxy-4-(3,6-dioxaheptyloxy)phenyl]-4-methyl-4-thiazolecarboxylic acid for use in treating iron overload | Active | 05-Aug-2016 | ||
| JP-2022163170-A | Dosing regimens for treating metal-induced diseases | Active | 05-Aug-2016 | ||
| AU-2017307566-A1 | Dosing regimens for treating metal-mediated conditions | Active | 05-Aug-2016 | A61K9/0019 |
Abfero Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Abfero Pharmaceuticals Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Deepwork Capital | Venture Capital | Minority | ||
| Innovate UK | Government | |||
| K2X | Venture Capital | Minority | ||
| Longwall Ventures | Venture Capital | Minority | ||
| University of Florida Investment Corporation | Limited Partner | Minority |
Abfero Pharmaceuticals FAQs
-
When was Abfero Pharmaceuticals founded?
Abfero Pharmaceuticals was founded in 2016.
-
Where is Abfero Pharmaceuticals headquartered?
Abfero Pharmaceuticals is headquartered in Boston, MA.
-
What is the size of Abfero Pharmaceuticals?
Abfero Pharmaceuticals has 2 total employees.
-
What industry is Abfero Pharmaceuticals in?
Abfero Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Abfero Pharmaceuticals a private or public company?
Abfero Pharmaceuticals is a Private company.
-
What is the current valuation of Abfero Pharmaceuticals?
The current valuation of Abfero Pharmaceuticals is .
-
What is Abfero Pharmaceuticals’s current revenue?
The current revenue for Abfero Pharmaceuticals is .
-
How much funding has Abfero Pharmaceuticals raised over time?
Abfero Pharmaceuticals has raised $5.43M.
-
Who are Abfero Pharmaceuticals’s investors?
Deepwork Capital, Innovate UK, K2X, Longwall Ventures, and University of Florida Investment Corporation have invested in Abfero Pharmaceuticals.
-
Who are Abfero Pharmaceuticals’s competitors?
Protagonist Therapeutics and Bond Biosciences are competitors of Abfero Pharmaceuticals.
-
When was Abfero Pharmaceuticals acquired?
Abfero Pharmaceuticals was acquired on 11-Nov-2021.
-
Who acquired Abfero Pharmaceuticals?
Abfero Pharmaceuticals was acquired by Pharmacosmos.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
